CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ChemGenex Pharmaceuticals Limited (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ChemGenex Pharmaceuticals Limited (ADR)
Level 4
199 Moorabool Street
Phone: +61 352239900p:+61 352239900 Geelong, VIC  3220  Australia Ticker: CXSPYCXSPY

This company is no longer actively traded on any major stock exchange.

Business Summary
ChemGenex Pharmaceuticals Limited (ChemGenex) is an integrated biopharmaceutical development company with specialize in the discovery and the development of oncology drugs. As of June 30, 2010, ChemGenex Pharmaceuticals Inc. and ChemGenex Europe SAS were 100% owned by ChemGenex Pharmaceuticals Limited. ChemGenex focuses on developing targeted medicines for the treatment of cancer by identifying and targeting the genetic components of a range of cancer types. The Company has two molecules in clinical development and has progressed its lead compound, omacetaxine, to regulatory submission in Europe and the United States. The Company has submitted Omacetaxine to United States and European regulators for approval in chronic myeloid leukemia (CML) patients who have failed the tyrosine kinase inhibitor (TKI) imatinib and have the T315I point mutation. ChemGenex’s other development stage molecule Quinamed, has completed phase IIa clinical trials in a range of solid cancers.
(Source: ARS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20106/30/2010YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Financial Officer, Chief Operating Officer James A.Campbell 7/1/2011 1/1/2002
Chief Medical Officer, Senior Vice President Adam R.Craig 1/1/2010 10/7/2007
Senior Vice President, Chief Commercial Officer ThomasDeZao 7/20/2009 7/20/2009
6 additional Officers and Directors records available in full report.

Business Names
Business Name
ChemGenex Pharmaceuticals Limited (ADR)
CHEMGENEX PHARMACEUTICALS LTD
CXSPY

General Information
Number of Employees: 19 (As of 6/30/2010)
Outstanding Shares: 283,348,870 (As of 2/17/2011)
Shareholders: 6,642
Stock Exchange: OTC
Fax Number: +61 352290100


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023